XiaoMi-AI文件搜索系统
World File Search Systemclinically
中心氧气
SNV：单核苷酸变体； Indels：小插入/删除； CNV：副本编号变化； UPD：单亲疾病； mtDNA：线粒体DNA * CNV检测软件灵敏度> 95％；但是，对于重复和同源区域（例如伪基因）以及跨越两个或更少外显子的事件，可能会降低这种敏感性。**质量低和/或不清楚的变体通过正交方法确认：SNV和Indels通过Sanger测序； CNVs by Multiplex ligation-dependent probe amplification (MPLA), quantitative polymerase chain reaction (qPCR) or chromosomal microarray (CMA) *** Screening of UPD is performed using an in-house algorithm for Mendelian Inheritance Errors (MIE) to detect runs of homozygosity (ROH) for the well-known clinically relevant chromosomal regions Guaranteed internal必要时使用CMA进行验证测试。
epcoritamab（epkinly）
Evidence from 1 ongoing phase I/II open-label, single-arm study (EPCORE NHL-1, which included 157 patients with r/r LBCL) suggested that treatment with epcoritamab may result in clinically meaningful improvements in median overall survival (OS) (OS = 18.5 months; 95% confidence interval [CI], 11.7 to |||| ) and progression-free survival (PFS) (PFS = 4.4个月; 95％CI，3.0至8.8）。在12个月时对OS和PFS进行其他里程碑分析|||| |||||| ||| ||||||和18个月|||| |||||| ||| ||||||支持生存分析。epcoritamab与|||||的临床有意义的完整响应（CR）相关联||| ||| ||| || |||||和持久的响应（响应的中值持续时间[dor] = ||| ||||||; 95％CI，9.7 to |||||）。EPCORE NHL-1研究的结果表明，与健康相关的生活质量（HRQOL）没有损害。
药物名称：asciminib
基线：CBC＆DIFF，血小板，肌酐，碱性磷酸酶，Alt，总胆红素，LDH，LDH，钠，钾，钾，TSH，TSH，早晨血清皮质醇，胸部X射线，胸部X射线基线必需的结果，必须进行首次治疗。 Before each treatment: CBC & Diff, platelets, creatinine, alkaline phosphatase, ALT, total bilirubin, LDH, sodium, potassium, TSH, creatine kinase, random glucose If clinically indicated: chest x-ray, morning serum cortisol, lipase, serum or urine HCG (required for women of child bearing potential if pregnancy suspected), free T3 and free T4，血清ACTH水平，睾丸激素，雌二醇，FSH，LH，ECG每周电话护理评估在治疗时（可选）时副作用的迹象和症状。预定：
两个流的故事：来自人类行为和神经精神病学的增强学习模型
从人类决策的行为研究中汲取灵感，我们在这里提出了一个更一般，更灵活的参数框架，用于加强学习，将标准Q学习扩展到处理积极和负面奖励的两流模型，并允许将广泛的奖励处理偏见 - 使人相互作用的重要组成部分，使得跨越多种多样的社会的重要组成部分，以实现跨越的范围。系统以及与正常奖励处理中断相关的各种神经精神疾病。From the computational perspective, we observe that the proposed Split-QL model and its clinically inspired variants consistently outperform standard Q-Learning and SARSA methods, as well as recently proposed Double Q-Learning approaches, on simulated tasks with particular reward distributions, a real-world dataset capturing human decision-making in gambling tasks, and the Pac-Man game in a lifelong learning setting across different reward stationarities.
levemir®Flexpen®（胰岛素detemir（rys））解决方案...
胰岛素dletemir在血浆中与蛋白质结合的97％，而与性别无关。The results of in vitro studies do not suggest any clinically relevant albumin binding interactions between insulin detemir and fatty acids or other protein-bounds drugs (such as warfarin, frusemide, tolbutamide, diazepam, glibenclamide, nicardipine, repaglinide, aspirin or valproic acid) or other drugs known to bind to domains IIA and IIIA of the albumin molecule.由于每个胰岛素detemir分子的血浆中可用的白蛋白结合位点（约40万）过量（约400 000），因此很少有风险较低的白蛋白浓度较低，因此某些疾病状态（例如肾病综合征）（例如肾病综合征）可能会影响与游离胰岛素detemir或可能发生这种急性移位的比例。这得到了体外研究以及临床试验计划的亚组分析的支持。尽管如此，严重低藻症患者的数据有限。
Lewisham Medicines优化团队新闻
- 是否针对医学诊断的适应症（即缺乏症）（<25nmol/l或<10mcg/l）规定了维生素D？- 高剂量维生素D是否以治疗治疗期限以外的处方维生素D缺乏症？- 纠正剂量治疗后，应鼓励患者购买维护剂量OTC（Valupak D3 1,000单位（0.01英镑/片剂） - 患者是否有资格通过理事会的维生素D方案获得维生素D？- Where clinically indicated + patient is not eligible for Council's vitamin D scheme + exempt from NHSE self-care directive ,vitamin D may be prescribed by brand in line with local guidance - There are no colecalciferol 2,000 unit preparations recommended in the local guidance, can this be changed to a locally recommended colecalciferol preparation (Stexerol-D3 1,000 unit tablets)?- 目前在所有患者中是否安全开处方？
erythropoietin-for-ckd-scg-scg-1月2023.pdf
•启动并稳定患者对促红细胞生成素的治疗•根据血红蛋白水平和其他临床参数改变促红细胞生成素剂量•开出嗜寄居系统，通过家庭护理系统•测量HB，CRP，CRP，CRP，FERRITIN，FERRITIN和ARTER OFFERTINCT•定期稳定（TSAT）和四个星期，直到有四个星期，直到有四个星期，直到进行了四个星期，直到进行四个星期，直到进行四个星期，直到进行四个星期，直到进行四个星期，直至 a shared care arrangement from the patient's GP when the patient's treatment has been stabilised and a shared care arrangement for monitoring is clinically appropriate • Clinical review of patient by routine clinic follow-up (at least every 12 months) • Supervise the management of anaemia including any folate and vitamin B 12 deficiency • Notify the patient's GP of:
comasp®Cefiderocol0.008-128 RX仅
comasp®Cefiderocol0.008-128是一种定量的肉汤微稀释方法，用于体外测定细菌的抗菌易感性。comasp®Cefiderocol由聚苯乙烯微量滴定面板组成，其中含有冻干浓度的头孢菌和培养基的管（铁耗尽的阳离子调整后的Mueller Hinton肉汤），用于确定使用过夜的抑制性抑制性浓度（MIC）使用过夜的抑制性浓度（MIC）使用过夜抑制性（MIC）。COMASP®CEFIRECOL以0.008-128 µg/ml的浓度应在16-20小时的孵育时解释。ComASP ® Cefiderocol can be used to determine the MIC of cefiderocol against the following microorganisms for which cefiderocol has been shown to be active clinically and in vitro according to the FDA drug approved label: Acinetobacter baumannii complex Escherichia coli Enterobacter cloacae complex Klebsiella pneumoniae Proteus mirabilis Pseudomonas该方法的铜绿泥沙
pdurs思想
我们都熟悉药物磁盘组合产品的概念，您可能听说过“伴侣应用程序”几乎没有临床利益。With th e rise of clinically validated software making medical claims, there are an increasing number of pharmaceutical companies that are pairing their drugs w ith a software that supports the patient on their journey with that drug.. Let's re wind to 2017 with Propellor attaching to inhalers, Proteus surrounding a pill w ith a sensor, Welldoc demonstrating a strong benefit in chronic care manag ement, Akili treating ADHD, and software interventions就像freespira一样，在硬件组件中。快进了7年，必须为FDA的远见而鼓掌，因为软件作为医疗设备（SAMD）的演变与发布FDA对PD URS的指导草案的发布完全相吻合，该草案应在2025年完成。现在，我们有一种更清晰的方法来构建软件，以为药物提供更多的好处，并具有对患者的积极效果。